MedDataX Logo

Clinical Outcomes of Endoscopic Resection for Treating WHYX Lesion

NCT ID: NCT01451034

Last Updated: 2011-10-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

872 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-01-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Endoscopically, WHYX cancers demonstrated a vague extent of tumor spread due to pale color changes in both the background atrophic and metaplastic gastric mucosa. However, the clinical outcomes of WHYX cancers after endoscopic resection are unknown. The aim of this study was to evaluate clinical outcomes of WHYX cancers after endoscopic resection.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

WHYX Lesion Extremely Well Differentiated Intestinal-type Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

WHYX cancer group

WHYX cancer diagnosed by pathologic report

Group Type ACTIVE_COMPARATOR

WHYX cancer group

Intervention Type PROCEDURE

WHYX cancer diagnosed by pathologic report

non-WHYX cancer group

all cancer except WHYX cancer diagnosed by pathologic report

Group Type PLACEBO_COMPARATOR

WHYX cancer group

Intervention Type PROCEDURE

WHYX cancer diagnosed by pathologic report

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

WHYX cancer group

WHYX cancer diagnosed by pathologic report

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* From January 2009 to December 2010 enrolled 872 patients with EGC

Exclusion Criteria

* EGC with regional lymph node metastasis in radiologic finding endoscopically suspicious submucosal invasion
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Samsung Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Samsung Medical Center

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011-08-022

Identifier Type: -

Identifier Source: org_study_id